Thomas Ryll - 30 Jun 2021 Form 4 Insider Report for ImmunoGen, Inc.

Reporting relationship: SVP, Technical Operations
Issuer ticker: N/A
Reported as of: 30 Jun 2021
Net transaction value: +$21,246
SEC form: 4
Accepted by SEC: 02 Jul 2021, 16:18:56 UTC
Source filing: View source filing
Reporting owner signature: /s/ Joseph J. Kenny, attorney in fact

Key filing fact

Thomas Ryll filed Form 4 for ImmunoGen, Inc. on 02 Jul 2021.

Key facts

This page summarizes Thomas Ryll's Form 4 filing for ImmunoGen, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2021, 16:18.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$21,246.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMGN transaction

Common Stock

Award

Transaction value: $21,246
Shares: +3,849
Change %: +4.8%
Price: $5.52
Shares after: 84,714
Date: 30 Jun 2021
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2021 through June 30, 2021.

Footnote F2

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021.